487 results on '"Valteau-Couanet, D."'
Search Results
2. High-Dose Therapy Followed by Bone Marrow Rescue in Pediatric Solid Tumors
3. Spécificités pharmacologiques en oncologie pédiatrique
4. Évaluation et optimisation des pratiques de perfusion en oncologie pédiatrique
5. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
6. Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique
7. Toxicités cardiaques des anthracyclines en oncologie pédiatrique : de la clinique à la pharmacogénétique
8. La distraction pendant les soins, pensée par les parents d’enfants pris en charge en oncologie
9. Évaluation de l’intérêt de la relaxation chez les préadolescents, les adolescents et les jeunes adultes en cours de traitement pour un cancer à l’Institut Gustave-Roussy
10. Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution
11. Tandem high-dose chemotherapy with thiotepa and busulfan–melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients
12. Busulfan–Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed–unexposed study evaluating the clinical impact of the order of drug administration
13. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
14. Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults
15. PD-0923 Increasing access to highly specialized radiation treatments: the example of pediatric brachytherapy
16. RISK FACTORS WITHIN THE EUROPEAN HIGH RISK NEUROBLASTOMA HR-NBL1/SIOPEN TRIAL: PH-O120
17. THE ROLE OF MEGATHERAPY (MGT) AND STEM CELL TRANSPLANTATION (SCT) IN HIGH RISK EWING TUMOURS: MORE THAN 30 YEARS OF EBMT ACTIVITY.: PH-O100
18. Chapitre 12 - Spécificités pharmacologiques en oncologie pédiatrique
19. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
20. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
21. Chimiothérapie à hautes doses et autogreffe en oncologie pédiatrique
22. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
23. Neuroblastoma
24. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy
25. Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial
26. Le sujet et le handicap : accompagnement neuropsychologique et psychologique à long terme d’enfants atteints de cancer
27. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)
28. Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation
29. Intravascular catheter-related bloodstream infection caused by Abiotrophia defectiva in a neutropenic child
30. How do parents perceive high-dose chemotherapy and autologous stem cell transplantation for their children
31. In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children
32. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
33. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
34. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution
35. Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumour: impact on survival: P572
36. Indication and frequencies of megatherapy and autologous SCT activity in paediatric solid tumours in Europe: O436
37. The Bu-Mel experience in the paediatrics department of the Institut Gustave Roussy, Villejuif, France: analysis of toxicity and efficacy: 253
38. Early high-dose treatment: SCT results from the European High Risk Neuroblastoma Study: O173
39. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure
40. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors
41. Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial
42. Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors
43. Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials
44. Délais diagnostiques des sarcomes d’Ewing de l’enfant : distribution, déterminants et conséquences
45. Ovarian toxicity after high-dose chemotherapy without total body irradiation and without busulfan
46. Monocyte count at diagnosis of invasive aspergillosis is a major prognostic factor for death after haematopoietic stem cell transplantation
47. Le pronostic du neuroblastome de l'enfant. Méthodes d'étude et utilisation en pratique clinique
48. Neuroblastomes localisés du nouveau-né : 52 cas traités de 1990 à 1999
49. Results of Nb 97 SFOP Protocol in children > 1 year with a stage 4 neuroblastoma
50. Loi Léonetti en oncologie pédiatrique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.